India
India Multiple Sclerosis Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
India · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
China at $2.57 Bn. India (this report) at 5.7% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$377.4 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $551.9 Mn | — | — |
| 2025 (base) | $583.3 Mn | +$31.5 Mn | — |
| 2026 (forecast) | $616.6 Mn | +$33.2 Mn | +5.7% |
| 2027 (forecast) | $651.7 Mn | +$35.1 Mn | +11.7% |
| 2028 (forecast) | $688.9 Mn | +$37.1 Mn | +18.1% |
| 2029 (forecast) | $728.1 Mn | +$39.3 Mn | +24.8% |
| 2030 (forecast) | $769.6 Mn | +$41.5 Mn | +31.9% |
| 2031 (forecast) | $813.5 Mn | +$43.9 Mn | +39.5% |
| 2032 (forecast) | $859.9 Mn | +$46.4 Mn | +47.4% |
| 2033 (forecast) | $908.9 Mn | +$49.0 Mn | +55.8% |
| 2034 (forecast) | $960.7 Mn | +$51.8 Mn | +64.7% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$12.33 Bn
China
$2.57 Bn
Canada
$2.43 Bn
Japan
$1.55 Bn
Germany
$1.05 Bn
UK
$755.0 Mn
France
$739.5 Mn
Italy
$703.0 Mn
Brazil
$627.4 Mn
Ecuador
$555.8 Mn
India (this report)
$583.3 Mn
Spain
$468.3 Mn
Mexico
$475.3 Mn
Saudi Arabia
$447.7 Mn
Russia
$303.3 Mn
Australia
$313.0 Mn
New Zealand
$259.2 Mn
South Africa
$163.4 Mn
UAE
$142.7 Mn
Egypt
$77.1 Mn
Philippines
$67.2 Mn
Malaysia
$42.1 Mn
Hong Kong
$39.6 Mn
Thailand
$37.9 Mn
Singapore
$31.4 Mn
Kenya
$19.6 Mn
Multiple sclerosis drugs reduce relapses and slow disability in this immune disease of the brain and spinal cord.
Key segments of the multiple Sclerosis Drugs market include drug class (Anti-CD20 Antibodies, S1P Modulators and Interferons) and route (Infusion, Injectable and Oral).
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the multiple Sclerosis Drugs market.
Biomarker-guided treatment, earlier diagnosis and new device-based therapies give the multiple Sclerosis Drugs market strong room to grow.
Hard-to-reach brain targets, high failure rates in trials, side effects and high prices for new therapies hold back the multiple Sclerosis Drugs market.
The multiple Sclerosis Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for multiple Sclerosis Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in India.
What doctors and scientists are doing in Multiple Sclerosis Drugs right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
India · 3 shared keywords
India · 3 shared keywords
India · 2 shared keywords
India · 2 shared keywords
India · 2 shared keywords
India · 2 shared keywords
Medical Devices · India
Healthcare Services · India
Healthcare Services · India
Digital Health · India
Digital Health · India
Medical Devices · India
